Graf Acquisition Corp. IV (GFOR) Adjourns NKGen Completion Vote for Third Time
by Nicholas Alan Clayton on 2023-09-14 at 9:28am

Graf Acquisition Corp. IV (NYSE:GFOR) announced that it adjourned yesterday’s completion vote for its combination with NKGen Biotech without conducting any business and will reopen proceedings at 10 am ET September 20.

At issue at this point is neither vote turnout, nor approval, but Graf IV’s continued effort to bring in additional financing to the deal in light of redemptions. This new cash may be in the form of equity, debt, grants or other equity-linked securities, but must be enough to get it over the $50 million minimum cash condition in the deal, according to its press release.

Graf IV would still have some time to postpone things further, but not much as its transaction deadline is set for September 25. This is the third time it has adjourned this completion vote and it went into this string of meetings with about $62.2 million in trust.

At announcement, Graf IV’s combination included a backstop of up to $25 million funded by NKGen’s majority shareholder NKMax (KOSDAQ:182400) and it has not yet divulged what its preliminary redemption numbers are looking like.

The $160 million combination was initially announced in April of this year. Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions like Parkinson’s and Alzheimer’s.

Last month, NKGen announced that it had dosed the first patient with its candidate SNK-02 as a part of Phase I studies into the its efficacy in treating solid tumors.

 

Recent Posts
by Kristi Marvin on 2024-06-22 at 11:30am

Terms Tracker for the Week Ending June 21, 2024 Programming Note: An abbreviated version of the Terms Tracker will be posted next week.  In light of the end of the quarter, we will be busy putting together our Half-Year report which should be posted the first week of July.  Welcome to our weekly column where...

by Nicholas Alan Clayton on 2024-06-21 at 11:46am

Future Vision II (NASDAQ:FVNNU) has filed for a $50 million IPO to hunt for a TMT target in Asia including intelligent chips, 5G and other emerging technologies there. Given the heightened competition and trade protectionism around these technologies lately, it is interesting that Future Vision II hasn’t ruled out combining with a Chinese target. In...

by Nicholas Alan Clayton on 2024-06-21 at 8:12am

At the SPAC of Dawn Every public company wants retail investor engagement, but once brought along, those investors require a bit of educating as well. Nuclear fission firm Oklo (NYSE:OKLO) is discovering that this week as it made a point to put out a press release explaining that its most recent S-1 filing was a...

by Nicholas Alan Clayton on 2024-06-20 at 3:41pm

Voyager (NASDAQ:VASHU) has filed for a SPAC IPO featuring many of the now increasingly familiar terms pushed by underwriter Cantor Fitzgerald over the past month, but does include a novel dollar figure for its raise at $261 million, before any over-allotments. Outside of this, Voyager’s trust is funded to 100.00% with $10.00 per unit to...

by Kristi Marvin on 2024-06-20 at 12:29pm

Eleven new SPACs have filed since the beginning of June, and the number is 12 if we count the May 31st filing of Graf Global Corp.  Seven of those 12 are being underwritten by Cantor, which has always been a very active SPAC underwriter. But you know who else used to be very active? Credit...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved